DE602006013003D1 - Verfahren und zusammensetzungen zur impfung von tieren mit prrsv-antigenen mit verbesserter immunogenität - Google Patents

Verfahren und zusammensetzungen zur impfung von tieren mit prrsv-antigenen mit verbesserter immunogenität

Info

Publication number
DE602006013003D1
DE602006013003D1 DE602006013003T DE602006013003T DE602006013003D1 DE 602006013003 D1 DE602006013003 D1 DE 602006013003D1 DE 602006013003 T DE602006013003 T DE 602006013003T DE 602006013003 T DE602006013003 T DE 602006013003T DE 602006013003 D1 DE602006013003 D1 DE 602006013003D1
Authority
DE
Germany
Prior art keywords
prrsv
pigs
compositions
antigenes
major surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006013003T
Other languages
English (en)
Inventor
Israrul H Ansari
Fernando A Osorio
Asit K Pattnaik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska
Original Assignee
University of Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska filed Critical University of Nebraska
Publication of DE602006013003D1 publication Critical patent/DE602006013003D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006013003T 2005-08-30 2006-08-30 Verfahren und zusammensetzungen zur impfung von tieren mit prrsv-antigenen mit verbesserter immunogenität Active DE602006013003D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71235705P 2005-08-30 2005-08-30
PCT/US2006/033990 WO2007040876A2 (en) 2005-08-30 2006-08-30 Methods and compositions for vaccination of animals with prrsv antigens with improved immunogenicity

Publications (1)

Publication Number Publication Date
DE602006013003D1 true DE602006013003D1 (de) 2010-04-29

Family

ID=37906634

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006013003T Active DE602006013003D1 (de) 2005-08-30 2006-08-30 Verfahren und zusammensetzungen zur impfung von tieren mit prrsv-antigenen mit verbesserter immunogenität

Country Status (13)

Country Link
US (1) US7608272B2 (de)
EP (1) EP1929047B1 (de)
JP (1) JP2009506129A (de)
KR (1) KR20080064813A (de)
CN (1) CN101300363A (de)
AT (1) ATE461295T1 (de)
BR (1) BRPI0615610A2 (de)
CA (1) CA2620667A1 (de)
DE (1) DE602006013003D1 (de)
DK (1) DK1929047T3 (de)
ES (1) ES2343371T3 (de)
PL (1) PL1929047T3 (de)
WO (1) WO2007040876A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1962900A2 (de) * 2005-11-29 2008-09-03 Iowa State University Research Foundation, Inc. Identifizierung von schützenden antigen-determinanten des prrs-virus (porcine reproductive and respiratory syndrome virus) und ihre verwendungen
EP1792996A1 (de) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nukleinsäuren, kodierend für Impfstoffe gegen den reproduktiven und respiratorischen Syndrom Virus (prrsv)
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
US8142788B2 (en) * 2007-04-30 2012-03-27 Mj Biologics, Inc. PRRSV GP5 based compositions and methods
KR101101386B1 (ko) * 2008-12-04 2012-01-02 주식회사 바이오리쏘스 북미형 ｐｒｒｓｖ에 특이적인 면역원성 펩티드 및 그의 용도
BRPI1009455A2 (pt) 2009-03-10 2016-03-01 Baylor Res Inst anticorpos anti-c40 e usos dos mesmos
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
CN102770457A (zh) 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
TWI391487B (zh) * 2010-05-04 2013-04-01 Univ Nat Taiwan 以植物生產之豬生殖與呼吸道綜合症口服疫苗及其用途
UA108902C2 (uk) * 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
US10160789B2 (en) * 2011-03-14 2018-12-25 University Of Louisville Research Foundation, Inc. Polypeptides having immunoactivating activity and methods of producing the same
EP2688592A4 (de) 2011-03-25 2015-07-22 Baylor Res Inst Zusammensetzungen und verfahren zur immunisierung gegen den hepatitis-c-virus
BR112013028605A2 (pt) 2011-05-07 2017-01-17 Avi Mex S A De C V Lab vetor viral, vacina recombinante contra prrs e uso de uma vacina
KR101420850B1 (ko) * 2011-05-30 2014-08-13 건국대학교 산학협력단 돼지 생식기 호흡기 증후군 바이러스 유사입자 및 이를 이용한 백신
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
CN102559611B (zh) * 2011-06-23 2015-04-22 江苏省农业科学院 一种无筛选标记的双表达重组mva病毒及其构建方法
CN102351952B (zh) * 2011-10-19 2015-07-01 中国医学科学院基础医学研究所 一种低糖化突变体干扰素-λ1、其表达、纯化方法及其应用
US8906385B2 (en) 2011-12-01 2014-12-09 University Of Maryland, College Park Interferon-inducing porcine reproductive and respiratory syndrome virus isolate
EP3992210A1 (de) 2014-01-13 2022-05-04 Baylor Research Institute Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
US10072046B2 (en) * 2014-03-21 2018-09-11 Nutech Ventures Non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) and methods of using
TWI554609B (zh) * 2014-11-19 2016-10-21 國立屏東科技大學 抗豬生殖與呼吸綜合症病毒感染之重組融合抗原基因、重組融合抗原蛋白及含彼之次單位疫苗組成物
US10758605B2 (en) 2015-06-29 2020-09-01 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
CN105400745B (zh) * 2015-12-04 2018-11-13 南京农业大学 一种猪繁殖与呼吸综合征病毒基因工程毒株及其灭活疫苗和疫苗制备方法
CN106177945A (zh) * 2016-08-25 2016-12-07 芜湖英特菲尔生物制品产业研究院有限公司 一种猪疫苗用免疫增强剂、其制备方法及应用
CN107653254B (zh) * 2017-09-22 2020-12-25 龙岩学院 一种猪繁殖与呼吸综合症病毒重组orf5基因及其制备方法
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR102335864B1 (ko) * 2018-12-27 2021-12-06 주식회사 바이오포아 돼지 생식기 및 호흡기 증후군 바이러스의 키메라 바이러스 및 이를 이용한 백신
WO2020138761A1 (ko) * 2018-12-27 2020-07-02 주식회사 바이오포아 돼지 생식기 및 호흡기 증후군 바이러스의 키메라 바이러스 및 이를 이용한 백신

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053787A1 (en) * 1999-03-08 2000-09-14 Id-Lelystad, Instituut Voor Dierhouderij En Dierg Ezondheid B.V. Prrsv vaccines
EP0839912A1 (de) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Ansteckende Klone von RNA-Viren und darauf basierende Impfstoffe und diagnostisches Verfahren
NZ501264A (en) 1998-12-22 2001-09-28 Pfizer Prod Inc Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
EP1350840B1 (de) * 2002-04-05 2012-05-09 Boehringer Ingelheim Vetmedica GmbH Sequenz Positionen zur Anpassung bei PRRSV

Also Published As

Publication number Publication date
CA2620667A1 (en) 2007-04-12
CN101300363A (zh) 2008-11-05
EP1929047A2 (de) 2008-06-11
JP2009506129A (ja) 2009-02-12
ES2343371T3 (es) 2010-07-29
WO2007040876A2 (en) 2007-04-12
KR20080064813A (ko) 2008-07-09
EP1929047A4 (de) 2009-05-06
EP1929047B1 (de) 2010-03-17
US20080233083A1 (en) 2008-09-25
BRPI0615610A2 (pt) 2011-05-24
WO2007040876A3 (en) 2007-06-07
ATE461295T1 (de) 2010-04-15
DK1929047T3 (da) 2010-07-12
PL1929047T3 (pl) 2010-08-31
US7608272B2 (en) 2009-10-27

Similar Documents

Publication Publication Date Title
DE602006013003D1 (de) Verfahren und zusammensetzungen zur impfung von tieren mit prrsv-antigenen mit verbesserter immunogenität
CY1124202T1 (el) Εμβολια ανασυνδυασμενου zika
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
NL300919I2 (nl) Brodalumab
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
NO20082073L (no) Anti-myostatin-antistoffer
WO2005120565A3 (en) Sars vaccines and methods to produce highly potent antibodies
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
EA200901154A1 (ru) Растворимые слитые белки il17ra/rc и родственные способы
NO20082167L (no) Anti-Myostatin-antistoffer
RU2016111934A (ru) Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы
ATE512231T1 (de) Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
IL189313A (en) Virus-like particles as virus-paramixo vaccines, a method for their preparation and use
DK1898948T3 (da) Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
WO2011008974A3 (en) Rsv f protein compositions and methods for making same
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
IN2009CN03372A (de)
WO2007050095A3 (en) Improved vaccines and methods for using the same
WO2007098718A8 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
ATE469657T1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
BR112018007121A2 (pt) anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv
ATE519784T1 (de) An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition